Richard Webb, MD
Interventional Pain Medicine · Foley, ALNPI 1790125805
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 392 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Abbott accounts for 60.1% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $4,502 and has fallen 74.6% since, to $1,143 in 2025.
Across 392 payments — averaging $45.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$11K
- Medtronic$3K
- Boston Scientific$1K
- Vertiflex, Inc.$962
- AbbVie$360
- Nevro Corp.$251
- plus $2K from 24 others
Across 1 payment — averaging $820.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$820
What the payments were for
- Travel & lodging$5093%
- Food & beverage$17,33897%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 182 | $10,719 |
| Medtronic(2 entities) | 63 | $2,508 |
| Boston Scientific | 33 | $1,182 |
| Vertiflex, Inc. | 6 | $962 |
| AbbVie(2 entities) | 22 | $360 |
| Nevro Corp. | 4 | $251 |
| Collegium Pharmaceutical, Inc. | 15 | $214 |
| Relievant Medsystems, Inc. | 3 | $188 |
| Amgen | 9 | $187 |
| Teva Pharmaceuticals USA, Inc. | 12 | $182 |
| Spinal Simplicity, LLC | 2 | $166 |
| Smith+Nephew | 1 | $143 |
| Sanara Medtech Inc. | 1 | $125 |
| Nalu Medical, Inc. | 2 | $99 |
| Biohaven Pharmaceuticals, Inc. | 5 | $80 |
| Pfizer | 6 | $76 |
| Fidia Pharma USA Inc. | 4 | $50 |
| Scilex Pharmaceuticals Inc. | 4 | $48 |
| Arbor Pharmaceuticals, Inc. | 3 | $48 |
| MDD US Operations, LLC | 3 | $43 |
| Stryker | 1 | $42 |
| Vertos Medical, Inc. | 1 | $33 |
| Assertio Therapeutics, Inc. | 2 | $30 |
| Pacira Pharmaceuticals Incorporated | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $25 |
| Redhill Biopharma Inc. | 1 | $18 |
| Biodelivery Sciences International, Inc. | 1 | $15 |
| GRT US Holding, Inc. | 1 | $12 |
| Lilly USA, LLC | 1 | $11 |
| Electronic Waveform Lab, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Proclaim Family of SCS IPGs$2,809
- Proclaim IPG$1,617
- PROCLAIM$1,337
- Superion ISS$908
- INTELLIS ADAPTIVESTIM$838
- Intracept$245
- INTELLIS$237
- Senza Spinal Cord Stimulation System$217
- KYPHON EXPRESS II KYPHOPAK TRAY$174
- LENS 4K$143
- GENERAL PAIN MANAGEMENT$138
- HA MINUTEMAN G3-R$136
- ETERNA$133
- CellerateRx$125
- Vanta$120
- SPECTRA WAVEWRITER$113
How this compares
$17,847 in reported general payments places this provider in the 85th percentile of 33 interventional pain medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pregabalin | 992 | $25,330 |
| BelbucaBuprenorphine Hcl | 27 | $12,546 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 480 | $9,461 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 336 | $9,150 |
| Buprenorphine | 41 | $7,937 |
| Morphine Sulfate ErMorphine Sulfate | 94 | $4,139 |
| Tramadol Hcl | 404 | $3,703 |
| Gabapentin | 303 | $3,652 |
| Celecoxib | 133 | $2,531 |
| Tramadol Hcl ErTramadol Hcl | 50 | $2,297 |
| Fentanyl | 24 | $1,457 |
| Oxycodone Hcl | 78 | $1,179 |
| Tizanidine Hcl | 110 | $1,098 |
| Baclofen | 65 | $964 |
| Diclofenac Sodium | 84 | $846 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $214 | $12,54627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 33 interventional pain medicine providers in Alabama.
Other interventional pain medicine in Foley
- Michael KendrickBirmingham$90K
- Bradley WargoMuscle Shoals$41K
- Jacob VellaMontgomery$28K
- John IronsVestavia$22K
- Ryan AlmeidaBirmingham$14K
- Roberto ChangHoover$13K
- Bradley KatzMontgomery$12K
- Thomas MartinHoover$11K
- David HerrickMontgomery$9K
- Aaron ShinklePrattville$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.